Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors

PURPOSE: TAS-102 is a novel oral agent combining the antineoplastic thymidine-based nucleoside analogue, trifluridine, and the thymidine phosphorylase inhibitor, tipiracil (molar ratio 1:0.5). TAS-102 has shown good activity in refractory metastatic colorectal cancer with acceptable safety. No QT pr...

全面介紹

Na minha lista:
書目詳細資料
發表在:Cancer Chemother Pharmacol
Main Authors: Bendell, Johanna C., Patel, Manish R., Yoshida, Kenichiro, Seraj, Jabed, Weaver, Racquel, Lemech, Charlotte, Todaro, Thomas G., Pant, Shubham, Arkenau, Hendrik-Tobias
格式: Artigo
語言:Inglês
出版: Springer Berlin Heidelberg 2016
主題:
Original Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC4882359/
https://ncbi.nlm.nih.gov/pubmed/27151157
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3031-9
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍